Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced that the Israel Innovation Authority (IIA) has approved expanded support for its project to advance a robotic aseptic fill & finish platform, allowing the company to utilize the full approved grant budget of NIS 5 million over two years, approximately 66% of which is non-dilutive funding. The announcement, made via press release, underscores Scinai's commitment to enhancing its sterile biologics manufacturing capabilities.
The program supports the acquisition and validation of a fully automated robotic-arm aseptic fill & finish system aligned with EU GMP Annex 1 standards, with validation targeted for the third quarter of 2026. This investment is part of Scinai's broader CDMO expansion strategy following its acquisition of Recipharm Israel Ltd. and commercial collaboration with Recipharm. The integration strengthens its two-site manufacturing platform, which includes a biologics development and clinical manufacturing facility in Jerusalem and a small-molecule API development and GMP manufacturing site in Yavne.
The expanded grant support is significant as it allows Scinai to maximize non-dilutive funding, maintaining disciplined capital allocation while advancing critical infrastructure. The robotic fill & finish system is expected to enhance the company's ability to serve clients from preclinical development through Phase I/II clinical supply, including biologics process development, analytical method development, sterile fill and finish, and clinical cGMP manufacturing.
Through a strategic commercial collaboration agreement with Recipharm, Scinai offers clients a defined pathway from early clinical development to late-stage and commercial manufacturing within Recipharm's global network. This structure enables continuity of development, streamlined tech transfer, and reduced scale-up risk as programs advance. The CDMO unit primarily engages with early-stage and emerging biotech companies and mid-size pharmaceutical companies outsourcing early development programs.
In parallel, Scinai continues to advance its immunology R&D pipeline, including PC111, a first-in-class anti-FasL monoclonal antibody targeting orphan dermatologic indications, and next-generation NanoAb-based programs in inflammation. The company is seeking strategic partnerships, co-development agreements, and regional licensing opportunities to advance selected programs toward clinical validation.
For more details, the full press release is available at https://ibn.fm/SxadB. Additional updates on Scinai Immunotherapeutics can be found in the company's newsroom at https://ibn.fm/SCNI.
